Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 339 participants.

Also called NCT05130268

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 339 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05130268
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05130268. Randomized; no masking; primary purpose treatment. Start 2021-10-29 (actual); primary completion 2024-01-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation
Acronym
CHANGE-AFIB
Intervention (Drug)
Dronedarone
Lead sponsor
American Heart Association (class: other)
Collaborator
Duke Clinical Research Institute (class: other)
Collaborator
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct05130268
Content hash
16cf8e5034568fddfbeb5da74a5bc3816530c28309dff14faa894c418f307f6c